Personalis Inc (PSNL) Stock Price, Quote & News

Company Profile

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor an...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 650 752 1300

Fax: 650 752 1301

Website: www.personalis.com

Address:

6600 Dumbarton Circle, Fremont, United States

DiamondHandsDO Aug. 19 at 12:35 PM

$PSNL $MRNA this just makes the deal look even worse

1 · Reply

TripleWitch Aug. 19 at 12:32 PM

$MRK $PSNL $TEM let the bidding begin….

1 · Reply

OpenOutcrier Aug. 19 at 12:29 PM

$PSNL (+6.3% pre) Moving higher with $MRK & $MRNA; helps sequence these tumors and design these neoantigrn vaccines - @Banana_Oncology https://ooc.bz/l/111596

0 · Reply

hyperliquidated Aug. 19 at 12:12 PM

$PSNL i remember when this junk was the next big thing, stock was 30-40+ a share. Now getting bought out for next to nothing. every IPO investor lost money here. I see stock hit 2 bucks in '23 and '24 lol

1 · Reply

SelfMafia Aug. 19 at 11:58 AM

$TEM People just finding out that they used the $PSNL platform that $TEM now owns? $MRNA $XBI $MRK 😝

1 · Reply

SannieVerraderlijk Aug. 19 at 11:56 AM

$PSNL Holding for a $MRK bid

0 · Reply

Wax_Bean_futures Aug. 19 at 11:50 AM

$PSNL Moderna up 94% holy hell

0 · Reply

Wax_Bean_futures Aug. 19 at 11:29 AM

$PSNL Maybe we pop over $16 50 per share briefly so we can sell LOL

0 · Reply

Wax_Bean_futures Aug. 19 at 11:28 AM

$PSNL Please tell me some miracle happens, and the buyout deal is cancelled, or Somehow renegotiated

1 · Reply

Wax_Bean_futures Aug. 19 at 11:27 AM

$PSNL

0 · Reply

Personalis reports Q2 EPS (30c), consensus (28c)

2026-08-04T20:11:59.000Z - 14 days ago

Personalis says not providing guidance or conducting earnings call

TEM

Aug 4, 2026, 4:01 PM EDT - 14 days ago

Personalis Reports Second Quarter Results and Recent Highlights

Aug 4, 2026, 4:00 PM EDT - 14 days ago

Personalis Earnings release: Q2 2026

Aug 4, 2026, 4:00 PM EDT - 14 days ago

Personalis Quarterly report: Q2 2026

Jul 29, 2026, 9:39 PM EDT - 20 days ago

Halper Sadeh LLC is Investigating Whether FNWD and PSNL are Obtaining Fair Deals for their Shareholders

FNWD

Jul 27, 2026, 10:22 AM EDT - 22 days ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Luxfer Holdings PLC (NYSE – LXFR), Finward Bancorp (Nasdaq – FNWD), Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR)

LXFR

Jul 21, 2026, 10:46 AM EDT - 4 weeks ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)

NUVL

2026-07-21T10:41:24.000Z - 4 weeks ago

Personalis price target raised to $16.25 from $11 at BTIG

TEM

2026-07-20T20:18:32.000Z - 4 weeks ago

Tempus AI (TEM) Drops on $1.7B Personalis Deal; Needham Analyst Calls the Slide a “Market Misread”

TEM

2026-07-20T18:45:13.000Z - 4 weeks ago

Morgan Stanley sees strategic logic in Personalis deal despite financial hurdles

TEM

2026-07-20T18:20:22.000Z - 4 weeks ago

AI Daily: Tempus AI to acquire Personalis at enterprise value of $1.5B

AMTM GOOG GOOGL NVDA QMLS TEM XMTR

2026-07-20T16:00:42.000Z - 4 weeks ago

Midday Fly By: Domino’s reports mixed Q2, Tempus AI to acquire Personalis

AAPL ACHR AER AMC BA BABA BAM

2026-07-20T15:40:12.000Z - 4 weeks ago

Personalis downgraded to Hold from Buy at Needham

Jul 20, 2026, 10:44 AM EDT - 4 weeks ago

Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink

TEM

2026-07-20T14:10:32.000Z - 4 weeks ago

Personalis downgraded to Hold from Buy at Lake Street

TEM

2026-07-20T12:55:07.000Z - 4 weeks ago

Personalis trading resumes

Jul 20, 2026, 8:44 AM EDT - 4 weeks ago

Tempus to acquire Personalis for $1.5 billion

TEM

2026-07-20T12:35:54.000Z - 4 weeks ago

Tempus AI to acquire Personalis for $16.25 per share

TEM

2026-07-20T12:35:19.000Z - 4 weeks ago

Tempus AI to acquire Personalis for $16.25 per share

TEM

Jul 20, 2026, 8:30 AM EDT - 4 weeks ago

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

TEM

2026-07-20T12:25:09.000Z - 4 weeks ago

Personalis trading halted, news pending

2026-07-17T11:20:50.000Z - 4 weeks ago

Personalis price target raised to $17 from $12 at Needham

MRK TEM

2026-07-16T19:35:24.000Z - 4 weeks ago

Personalis attracting takeover interest, Street Insider says

MRK

2026-07-16T19:35:17.000Z - 4 weeks ago

Personalis moves off low after blog claims company exploring possible sale

2026-07-15T12:56:09.000Z - 4 weeks ago

Personalis price target raised to $18 from $10 at TD Cowen

2026-07-14T10:15:10.000Z - 5 weeks ago

Personalis’ NeXT Personal test granted UKCA marking

Jul 14, 2026, 6:00 AM EDT - 5 weeks ago

Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain

2026-07-09T11:00:23.000Z - 5 weeks ago

Personalis price target raised to $13 from $9 at Morgan Stanley

2026-06-09T10:45:09.000Z - 2 months ago

Personalis’ specimen collection kits obtain European Union CE-IVD mark

Jun 9, 2026, 6:00 AM EDT - 2 months ago

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

Jun 2, 2026, 6:00 AM EDT - 2 months ago

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

May 26, 2026, 6:00 AM EDT - 3 months ago

Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium

May 20, 2026, 6:00 AM EDT - 3 months ago

Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

May 14, 2026, 4:01 PM EDT - 3 months ago

Personalis to Participate in Upcoming Investor Events

May 13, 2026, 6:00 AM EDT - 3 months ago

Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors

May 12, 2026, 12:00 PM EDT - 3 months ago

Personalis Transcript: AGM 2026

May 7, 2026, 5:00 PM EDT - 3 months ago

Personalis Earnings Call Transcript: Q1 2026

May 7, 2026, 5:00 PM EDT - 3 months ago

Personalis Earnings release: Q1 2026

May 7, 2026, 5:00 PM EDT - 3 months ago

Personalis Quarterly report: Q1 2026

May 7, 2026, 4:01 PM EDT - 3 months ago

Personalis Reports First Quarter Results and Recent Highlights

Apr 23, 2026, 4:01 PM EDT - 4 months ago

Personalis to Announce First Quarter 2026 Financial Results

Apr 21, 2026, 6:00 AM EDT - 4 months ago

Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026

Apr 13, 2026, 6:00 AM EDT - 4 months ago

Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026

Apr 2, 2026, 8:00 AM EDT - 4 months ago

Personalis Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 4 months ago

Personalis Proxy statement: Proxy filing

Apr 1, 2026, 4:01 PM EDT - 4 months ago

Personalis to Participate in the 25th Annual Needham Virtual Conference

Mar 17, 2026, 4:00 PM EDT - 5 months ago

Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption

Mar 12, 2026, 6:00 AM EDT - 5 months ago

Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®

Feb 26, 2026, 5:00 PM EST - 6 months ago

Personalis Earnings Call Transcript: Q4 2025

Feb 26, 2026, 5:00 PM EST - 6 months ago

Personalis Annual report: Q4 2025

Feb 26, 2026, 5:00 PM EST - 6 months ago

Personalis Earnings release: Q4 2025

Feb 26, 2026, 4:01 PM EST - 6 months ago

Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

Feb 17, 2026, 4:01 PM EST - 6 months ago

Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference

Feb 12, 2026, 4:01 PM EST - 6 months ago

Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results

Feb 10, 2026, 6:00 AM EST - 6 months ago

Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance

Feb 2, 2026, 6:00 AM EST - 7 months ago

Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors

Jan 28, 2026, 4:01 PM EST - 7 months ago

Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 12, 2026, 4:00 PM EST - 7 months ago

Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™

Jan 8, 2026, 8:00 AM EST - 7 months ago

Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights

Dec 17, 2025, 6:00 AM EST - 8 months ago

Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors

Dec 11, 2025, 9:00 AM EST - 8 months ago

New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer

Nov 18, 2025, 4:01 PM EST - 9 months ago

Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 10, 2025, 9:00 AM EST - 10 months ago

Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer

Nov 4, 2025, 5:00 PM EST - 10 months ago

Personalis Earnings Call Transcript: Q3 2025

Nov 4, 2025, 5:00 PM EST - 10 months ago

Personalis Quarterly report: Q3 2025

Nov 4, 2025, 5:00 PM EST - 10 months ago

Personalis Earnings release: Q3 2025

Nov 4, 2025, 4:01 PM EST - 10 months ago

Personalis Reports Third Quarter 2025 Financial Results

Oct 21, 2025, 4:01 PM EDT - 10 months ago

Personalis to Announce Third Quarter 2025 Financial Results

Oct 16, 2025, 9:00 AM EDT - 10 months ago

Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing

Sep 15, 2025, 5:35 PM EDT - 1 year ago

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 10, 2025, 4:05 PM EDT - 1 year ago

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

Sep 3, 2025, 4:05 PM EDT - 1 year ago

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

Aug 27, 2025, 4:01 PM EDT - 1 year ago

Personalis to Participate in Upcoming Investor Conferences

Aug 5, 2025, 5:00 PM EDT - 1 year ago

Personalis Earnings Call Transcript: Q2 2025

Aug 5, 2025, 5:00 PM EDT - 1 year ago

Personalis Earnings release: Q2 2025

Aug 5, 2025, 5:00 PM EDT - 1 year ago

Personalis Quarterly report: Q2 2025

Aug 5, 2025, 4:01 PM EDT - 1 year ago

Personalis Reports Second Quarter 2025 Financial Results

Jul 22, 2025, 4:01 PM EDT - 1 year ago

Personalis to Announce Second Quarter 2025 Financial Results

Jul 9, 2025, 4:00 PM EDT - 1 year ago

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

TEM

Jun 3, 2025, 4:00 PM EDT - 1 year ago

Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

Jun 2, 2025, 4:00 PM EDT - 1 year ago

New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse

DiamondHandsDO Aug. 19 at 12:35 PM

$PSNL $MRNA this just makes the deal look even worse

1 · Reply

TripleWitch Aug. 19 at 12:32 PM

$MRK $PSNL $TEM let the bidding begin….

1 · Reply

OpenOutcrier Aug. 19 at 12:29 PM

$PSNL (+6.3% pre) Moving higher with $MRK & $MRNA; helps sequence these tumors and design these neoantigrn vaccines - @Banana_Oncology https://ooc.bz/l/111596

0 · Reply

hyperliquidated Aug. 19 at 12:12 PM

1 · Reply

SelfMafia Aug. 19 at 11:58 AM

$TEM People just finding out that they used the $PSNL platform that $TEM now owns? $MRNA $XBI $MRK 😝

1 · Reply

SannieVerraderlijk Aug. 19 at 11:56 AM

$PSNL Holding for a $MRK bid

0 · Reply

Wax_Bean_futures Aug. 19 at 11:50 AM

$PSNL Moderna up 94% holy hell

0 · Reply

Wax_Bean_futures Aug. 19 at 11:29 AM

$PSNL Maybe we pop over $16 50 per share briefly so we can sell LOL

0 · Reply

Wax_Bean_futures Aug. 19 at 11:28 AM

$PSNL Please tell me some miracle happens, and the buyout deal is cancelled, or Somehow renegotiated

1 · Reply

Wax_Bean_futures Aug. 19 at 11:27 AM

$PSNL

0 · Reply

arribaStocktrading Aug. 19 at 11:25 AM

$TEM Damn the torpedoes and full speed ahead. In case you didn't know, $PSNL provides the engine that makes Moderna's $MRNA melanoma vaccine possible. Moderna got a front page from the Wall Street Journal. This is BIG BIG BIG news.... and did I mention BIG???

0 · Reply

arribaStocktrading Aug. 19 at 11:12 AM

$PSNL Today would have been an absolutely huge day for Personalis. Grrrrr! At least I added to my $TEM position yesterday so there is that. We knew it all along! Pyrrhic victory now. $TEM to $80.

1 · Reply

Wax_Bean_futures Aug. 19 at 11:07 AM

$PSNL WOW, $MRNA flying today $TEM

0 · Reply

PatrickandFrankie Aug. 18 at 1:37 PM

$PSNL i’m starting to feel much better about this acquisition. We should have been more dollars but it’s still a win-win. IMHO

0 · Reply

ChurxyChurx Aug. 17 at 12:22 PM

$EYPT amazing! Next are: $OCGN $PSNL Wohoooo

1 · Reply

I_am_back_2day Aug. 13 at 1:28 PM

$PSNL $TEM Don’t listen to this without facts or just screen shot of RH.. Trust Google having investment here and they holding on to them

1 · Reply

ChurxyChurx Aug. 13 at 1:12 PM

$PSNL I sold this garbage. finally im out and I won't ever have to thing about this bankrupt shit company ever again. Happy day

0 · Reply

Truenorthtrades1 Aug. 13 at 4:06 AM

$TEM 👀 Check out the #shorts position here… this thing has some SERIOUS fuel! And then you have recent insider selling that makes you stop and ask: what in the world is going on here!? 🤔 The $PSNL deal still appears to be moving forward, with the transaction expected to close later this year or early 2027. Now, I’m NOT saying anything but, why is there individuals selling on the inside (August 2026)? Per open records. But when you combine the insider selling, millions of shares short, and nearly 6 (or so) days of average volume needed to cover… 👀 If buying pressure really shows up, could $TEM become a serious #shortsqueeze candidate? The setup is definitely interesting. 🚀 Not investment advice — just my opinion and opinion. $TEM BULL 🐂

0 · Reply

Enjoyycall Aug. 12 at 7:44 PM

$PSNL I'm in tape all day...

0 · Reply

arribaStocktrading Aug. 12 at 10:58 AM

$PSNL So let's recap. Personalis was never inevitable the way some stocks are. For years, they made front-loaded investments that Wall Street refused to acknowledge. Their quarterly results never fully told their story. So the stock ultimately dipped to $1/share and Wall Street was eagerly waiting for them with any number of toxic financing arrangements that would have sent the stock into a permanent spiral of harmful dilution. But management had other plans. They bypassed the Street with direct stock sales and partnerships that included direct stock purchases that kept the company well funded to meet their objectives. It took time but the superiority of their tech was validated by studies with the world's most prestigious oncology clinics. They will be a major player in MRD and Tempus AI will be reaping the benefits. Hopefully everything else in the Tempus arsenal will click so that legacy PSNL shareholders will ultimately benefit from the merger.

1 · Reply

ChurxyChurx Aug. 12 at 7:14 AM

$PSNL typical bankrupt garbage. ahhhhhh never seen such a stupid company..

0 · Reply

DILLIGAF_ Aug. 11 at 2:30 PM

$TEM With how large the institutional ownership of this stock is I imagine they're going to pump this so the cost of $PSNL per share is less and less

0 · Reply

Market Cap	1.45B
Revenue (ttm)	69.65M
Net Income (ttm)	-81.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-116.68%
Debt to Equity Ratio	0.00

Volume	1,025,300
Avg Vol	3,943,856
Day's Range	N/A - N/A
Shares Out	104.72M
Stochastic %K	52%
Beta	2.27
Analysts	Sell
Price Target	$13.88